Initiator Pharma A/S
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INIT.ST research report →
Companywww.initiatorpharma.com
Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. It develops IP2018, a monoamine reuptake inhibitor for the treatment of psychogenic erectile dysfunction; IPED2015 to treat patients suffering from organic erectile dysfunction; and IPTN2021 for targeting an orphan drug indication in severe neuropathic pain. The company's pre-clinical stage candidates include IPNP2015 for the treatment of chronic pain; and IPDP2015 for depression.
- CEO
- Claus Elsborg Olesen
- IPO
- 2017
- Employees
- 2
- HQ
- Copenhagen, DK
Price Chart
Valuation
- Market Cap
- $206.73M
- P/E
- -6.36
- P/S
- 0.00
- P/B
- 7.87
- EV/EBITDA
- -4.92
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -101.30%
- ROIC
- -90.34%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-14,010,158 · -108237.13%
- EPS
- $-0.23 · 0.00%
- Op Income
- $-18,200,820
- FCF YoY
- 100.00%
Performance & Tape
- 52W High
- $4.17
- 52W Low
- $2.56
- 50D MA
- $3.17
- 200D MA
- $3.14
- Beta
- 0.10
- Avg Volume
- 116.57K
Get TickerSpark's AI analysis on INIT.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our INIT.ST Coverage
We haven't published any research on INIT.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate INIT.ST Report →